Willow Bioscience (CSE:WLLW) is a synthetic biology company focused on producing pharmaceutical grade cannabinoids via industrial scale biosynthesis.
Willow has a world class team of academic and industrial scientists with a long history in medicinal plants who most recent program involved creating and scaling up a yeast strain to produce thebaine via biosynthesis.
Groundbreaking discoveries in biosynthesis.
Low Cost Production
World Class Team
Synthetic cannabinoids are much cheaper to produce than plant based.
$29M in funding secured.
Academic and industrial scientists with a long history in medicinal plants.
Willow Biosciences recently began trading on the Canadian Securities Exchange